mlg mouse lung fibroblasts Search Results


mouse mlg lung fibroblast cells  (Lonza)
90
Lonza mouse mlg lung fibroblast cells
In vitro characterization of MEDI-579 ( a ) TGFβ-1 stimulated <t>fibroblasts</t> produce PAI-1. The ability of this endogenously produced PAI-1 to inhibit protease in an assay dependent on the generation of active plasmin from exogenously added plasminogen is then measured. Cells with (+PAI-1) or without (-PAI-1) TGFβ-1 stimulation represent 0% or 100% plasmin activity respectively. MEDI-579 is able to inhibit PAI-1 produced from TGFβ-1 treated normal human lung fibroblasts (NHLFs) and mouse lung fibroblasts (MLgs) in this assay with pIC 50 = 9.8 ± 0.14 (10.5 nM) and 8.99 ± 0.12 (1.3 nM) respectively. Data shown are an average of four independent experiments ± s.e.m. ( b ) MEDI-579 does not block PAI-1 binding to vitronectin. Antibody 33B08 enhances conversion of active PAI-1 to the latent form and potently inhibits in this assay (IC 50 = 12.46 ± 0.45 nM; data is average of two experiments ± s.d.).
Mouse Mlg Lung Fibroblast Cells, supplied by Lonza, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse mlg lung fibroblast cells/product/Lonza
Average 90 stars, based on 1 article reviews
mouse mlg lung fibroblast cells - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

Image Search Results


In vitro characterization of MEDI-579 ( a ) TGFβ-1 stimulated fibroblasts produce PAI-1. The ability of this endogenously produced PAI-1 to inhibit protease in an assay dependent on the generation of active plasmin from exogenously added plasminogen is then measured. Cells with (+PAI-1) or without (-PAI-1) TGFβ-1 stimulation represent 0% or 100% plasmin activity respectively. MEDI-579 is able to inhibit PAI-1 produced from TGFβ-1 treated normal human lung fibroblasts (NHLFs) and mouse lung fibroblasts (MLgs) in this assay with pIC 50 = 9.8 ± 0.14 (10.5 nM) and 8.99 ± 0.12 (1.3 nM) respectively. Data shown are an average of four independent experiments ± s.e.m. ( b ) MEDI-579 does not block PAI-1 binding to vitronectin. Antibody 33B08 enhances conversion of active PAI-1 to the latent form and potently inhibits in this assay (IC 50 = 12.46 ± 0.45 nM; data is average of two experiments ± s.d.).

Journal: Scientific Reports

Article Title: Discovery and characterisation of an antibody that selectively modulates the inhibitory activity of plasminogen activator inhibitor-1

doi: 10.1038/s41598-019-38842-x

Figure Lengend Snippet: In vitro characterization of MEDI-579 ( a ) TGFβ-1 stimulated fibroblasts produce PAI-1. The ability of this endogenously produced PAI-1 to inhibit protease in an assay dependent on the generation of active plasmin from exogenously added plasminogen is then measured. Cells with (+PAI-1) or without (-PAI-1) TGFβ-1 stimulation represent 0% or 100% plasmin activity respectively. MEDI-579 is able to inhibit PAI-1 produced from TGFβ-1 treated normal human lung fibroblasts (NHLFs) and mouse lung fibroblasts (MLgs) in this assay with pIC 50 = 9.8 ± 0.14 (10.5 nM) and 8.99 ± 0.12 (1.3 nM) respectively. Data shown are an average of four independent experiments ± s.e.m. ( b ) MEDI-579 does not block PAI-1 binding to vitronectin. Antibody 33B08 enhances conversion of active PAI-1 to the latent form and potently inhibits in this assay (IC 50 = 12.46 ± 0.45 nM; data is average of two experiments ± s.d.).

Article Snippet: Normal human lung fibroblasts (NHLF) or mouse MLg lung fibroblast cells were plated (~20000/well, 96 well format; Lonza, Basel, Switzerland) and stimulated with rhTGFβ (100 pM; R&D Systems, Abingdon, UK) for 18 h to induce the expression of PAI-1.

Techniques: In Vitro, Produced, Activity Assay, Blocking Assay, Binding Assay